Search clinical trials for: Daclatasvir Asunaprevir

Total 155 results

National Institutes of Health Clinical Center (CC)
Bristol-Myers Squibb; National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV

HIV-HCV

United States
Sang Gyune Kim
Bristol-Myers Squibb; Korea University; Gachon University Gil Medical Center; Seoul... and other collaborators

Unknown

Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment (RELIF-C)

Chronic Hepatitis C

Korea, Republic of
Bristol-Myers Squibb

Completed

UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C

Hepatitis C Virus Infection

Japan
Myeong Jun Song
Bristol-Myers Squibb; Korea University Guro Hospital; Severance Hospital; Eulji... and other collaborators

Completed

The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure

Hepatitis C

Korea, Republic of
Foundation for Liver Research

Completed

Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients (ImmunoDual)

Chronic Hepatitis C

Netherlands
Tainan Municipal Hospital

Withdrawn

Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas

Hepatitis c
Bristol-Myers Squibb

Completed

Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

Hepatitis C

United States, Australia, France, Japan, Spain, Sweden, Canada, Germany, Mexico, Denmark, Italy, Korea, Republic of, Taiwan, Argentina, Brazil, Ireland, Poland, Puerto Rico, United Kingdom
Bristol-Myers Squibb

Completed

A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients

Hepatitis C

Japan
ANRS, Emerging Infectious Diseases
Bristol-Myers Squibb

Withdrawn

Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen (QUATTROTURBO)

Hepatitis C Virus Genotype 4 Infection

France
Kaohsiung Medical University Chung-Ho Memorial...
National Taiwan University Hospital; China Medical University Hospital; Chang... and other collaborators

Completed

Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV

Hepatitis C

Taiwan
Bristol-Myers Squibb

Completed

A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir

Hepatitis C Infection
Bristol-Myers Squibb

Completed

A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection

Hepatitis C

China, Korea, Republic of, Russian Federation
Bristol-Myers Squibb

Completed

Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

Chronic Hepatitis C

France, United States, Puerto Rico
Bristol-Myers Squibb

Completed

To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet

Hepatitis C

United States
Kirby Institute
Bristol-Myers Squibb

Withdrawn

Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism (HEPCOG-II)

Hepatitis C, Chronic

Australia
ANRS, Emerging Infectious Diseases
Bristol-Myers Squibb

Completed

Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders (QUADRIH)

HCV-HIV Co-Infection

France
Timothy Morgan, MD
Bristol-Myers Squibb; National Cancer Institute (NCI); VA Long Beach Healthcare...

Completed

Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus (RHACE 1)

Hepatitis C

United States
Bristol-Myers Squibb

Completed

Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual

Hepatitis C

China, Korea, Republic of, Taiwan
Bristol-Myers Squibb

Completed

A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects

Hepatitis C Virus Infection

Japan
Qing XIe
Gilead Sciences; Tigermed Consulting Co., Ltd

Recruiting

Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C (C-DIAMOND)

Hepatitis C, Chronic

China
Bristol-Myers Squibb

Completed

Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin

Hepatitis C
Hospital do Coracao

Completed

Antiviral Agents Against COVID-19 Infection (REVOLUTIOn)

COVID-19

Brazil
Bristol-Myers Squibb

Completed

UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

Hepatitis C

United States, Australia, Canada, France
Atea Pharmaceuticals, Inc.

Completed

Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection

Hepatitis C Virus Infection | Hepatitis C | Hepatitis C, Chronic | Chronic Hepatitis C | HCV Infection

Belgium, Mauritius, Moldova, Republic of
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

Hepatitis C | Chronic Hepatitis C | HCV | CHC

New Zealand
Bristol-Myers Squibb

Completed

Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) (Hallmark DUAL)

Hepatitis C Virus

France, Germany, Korea, Republic of, Spain, Taiwan, United States, Canada, Australia, Russian Federation, Austria, Israel, Italy, Netherlands, Argentina, Poland, United Kingdom, Ireland, New Zealand
Bristol-Myers Squibb

Completed

Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment

Hepatitis C

United States
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Completed

A Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects

Drug Interactions

China
Genuine Research Center, Egypt
Zeta Pharma Pharmaceutical Industries

Completed

Bioequivalence Study of Daclatasvir From Daclatasvir Zeta 60 mg Film Coated Tablets (Zeta Pharm Pharmaceutical Industries, Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

Healthy

Egypt
Bristol-Myers Squibb

Completed

Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325

Hepatitis C
ANRS, Emerging Infectious Diseases
Bristol-Myers Squibb

Completed

Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)

Hepatitis C Virus Genotype 4 Infection

France
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Unknown

SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C

Hepatitis C, Chronic

China
Ain Shams University

Recruiting

Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C Virus

Chronic HCV Infection

Egypt
ANRS, Emerging Infectious Diseases

Completed

DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C) (DRIVE-C)

Hepatitis C | Viral Hepatitis C | Drug Use

Vietnam
Bristol-Myers Squibb

Completed

A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects

Chronic Hepatitis C

United States, Puerto Rico
Egyptian Liver Hospital
Wadi El Nil Hospital

Completed

A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection

Hepatitis C

Egypt
Bristol-Myers Squibb

Completed

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials) (Hallmark QUAD)

Hepatitis C Virus

United States, Germany, Italy, Korea, Republic of, Sweden, Russian Federation, Canada, France, Argentina, Switzerland, Denmark, Taiwan, Netherlands, Spain, Mexico
Bristol-Myers Squibb

Withdrawn

A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)

Hepatitis C

France, Canada
Bristol-Myers Squibb

Completed

A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects

Chronic Hepatitis C

United States
Bristol-Myers Squibb

Terminated

Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection

Hepatitis C | Chronic Hepatitis

Australia, Spain
Assiut University

Recruiting

Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera

Hepatitis C, Chronic

Egypt
ANRS, Emerging Infectious Diseases

Recruiting

Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia (HEPEDIAC)

HCV Infection

Cambodia
Bristol-Myers Squibb

Completed

A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.

Hepatitis C

United States
Bristol-Myers Squibb

Completed

Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032

Hepatic Insufficiency

United States
Bristol-Myers Squibb

Completed

A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects

Chronic Hepatitis C

United States, Puerto Rico
Hospices Civils de Lyon

Completed

Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA

Hepatitis C

France
Bristol-Myers Squibb

Completed

Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease

Hepatitis C

United States
Assiut University

Unknown

Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients

Chronic Hepatitis c

Egypt
Bristol-Myers Squibb

No longer available

A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C

Chronic Hepatitis C

United States
Radboud University Medical Center

Completed

A Drug-drug Interaction Study Between Daclatasvir and Metformin (DATE-3)

Diabetes Mellitus | Hepatitis C | Insulin Resistance

Netherlands

3

Subscribe